Design Corp (DSGN) - צמיחת רווח נקי למניה אחת לשנה הנוכחית

Design Therapeutics is developing an RNA platform to create Syn-TEFs drugs against neuromuscular pathologies, awaiting future test results, while current R&D expenses are already priced in. After analyzing the year-over-year earnings per share growth on GURU.Markets, we find that -8.90 captures the current state of the parameter. The development of unique small molecules for genetic disorders provides the company with significant market leverage.

Design Therapeutics focuses on developing small molecules for the treatment of rare genetic pathologies, which renders the company independent of general macroeconomic cycles. The annual net income per share growth history illustrates the EPS dynamics relative to the previous year, allowing investors to promptly assess the impact of liquidity and drug development efficiency on the asset's fundamental value.